Oct 17 ,2025
Synopsis
European equities are set to open lower as Asian equities trade lower Friday. Renewed turbulence in US regional banking space after KRX fell 6% to four-month low. Selling has spilled over to Asian session with Japan banks under pressure.
China stocks extending losses, putting mainland and Hong Kong benchmarks on track for steep weekly declines. Major banks notable decliners in Japan amid fallout from US regional bank selloff. TSMC weighing on Taiwan's index. Korea flat. US contracts extending declines afterhours
US equities close lower in Thursday trading, ending off worst levels. Major indices still on track for solid weekly gains. Financials sector was a notable drag amid regional-bank credit concerns and underwhelming reports from P&C insurance and insurance brokers.
Friday sees, in central banks, BOE's Pill speech at 10:35BST at the Institute of Chartered Accountants in England and Wales Annual Conf BOE's Greene speech at 12noon BST at an Atlantic Council roundtable. ECB's Donnery speech /panellist at 13:00CET at event hosted at Institute of International Finance (IIF).
Economic: Eurozone Sep final CPI, Sweden Sep unemployment rate, Austria Sep final CPI, Portugal Sep PPI
In corporate news: EssilorLuxottica (EL.FP) reports Q3 revenue €6.87B vs StreetAccount €6.72B. Volvo (VOLV.B.SS) reports Q3 EPS SEK3.71 vs FactSet SEK4.11 [11 est, SEK3.57-4.94]. Warehouses de Pauw (WDP.BB) reports Q3 EPRA EPS €0.40 vs FactSet €0.40. Tomra Systems (TOM.NO) reports Q3 adj EPS €0.05 vs FactSet €0.07 [7 est, €0.04-0.08]; comments on FY25 outlook. COMET Holding trading update: Q3 revenue CHF102.5M vs FactSet 112.0M [2 est, CHF110-114M] (COTN.SW)
Trading Update: Pearson (PSON.LN)
Politics/Macro/World News
Top company news
Earnings/updates
EL.FP (EssilorLuxottica) -- reports Q3 revenue €6.87B vs StreetAccount €6.72B
CON.GR (Continental) -- reports preliminary Q3 revenue €5.0B vs. consensus €4.9B; provides additional preliminary metrics
VIRP.FP (Virbac) -- reports 9M revenue €1.10B, +6% vs year-ago €1.04B
MMB.FP (Lagardere) -- reports Q3 revenue €2.55B, +5% vs year-ago €2.42B
HLE.GR (FORVIA HELLA) -- reports 9M revenue €5.9B vs year-ago €5.9B
POXEL.FP (Poxel) -- reports FY 2024 net income (€18.3M) vs year-ago (€35.1M); updates on reorganization proceedings
COTN.SW (COMET Holding) -- trading update: Q3 revenue CHF102.5M vs FactSet 112.0M [2 est, CHF110-114M]
FLOW.NA (Flow Traders) -- reports September 2025 ETP market statistics
MERY.FP (Mercialys) -- provides end-September update
ALHG.FP (Louis Hachette Group SA) -- reports Q3 revenue €2.61B vs FactSet €2.58B [1 est]
M&A
NBG6.GR (N+£RNBERGER Beteiligungs-AG) -- Vienna Insurance Group announces purchase offer for NÜRNBERGER Beteiligungs-AG at price of €120.00 per share
HSBA.LN (HSBC Holdings) -- Limited pool of suitors for HSBC's Australian business - The Australian
IBE.SM (Iberdrola) -- has held talks with competitors about a combination with Scottish Power - FT
SMIN.LN (Smiths Group) -- announces proposed sale of Smiths Interconnect to Molex
IMCD.NA (IMCD) -- to acquire 100% of the shares in Dong Yang FT Corp; terms undisclosed
SAB.SM (Banco de Sabadell) -- CNMV announces outcome of takeover bid for Banco de Sabadell by Banco Bilbao Vizcaya Argentaria, S.A.; minimum threshold not reached
CF.CN (Canaccord Genuity Group) -- Canaccord Genuity in talks with bidders including CVC and Advent for its British wealth arm - Reuters
YIT.FH (Yit) -- agrees on sale and construction of three residential buildings in Prague, Czech Republic - project value for €25M
M12.GR (M1 Kliniken) -- 85% subsidiary HAEMATO AG to sell HAEMATO Pharm GmbH to the PHOENIX group
HGT.LN (HgCapital Trust) -- Follow-up: Hg announces full exit of GTreasury
Healthcare
BAYN.GR (Bayer AG) -- FDA grants orphan drug designation to AskBio for treatment of Pompe disease
MRK.GR (Merck KGaA) -- EMD Serono announces agreement with US government to expand access to IVF therapies
ALCLS.FP (Cellectis SA) -- Cellectis' R&D Day highlights lasme-cel's potential to address significant unmet need for patients with r/r b-all
AB.FP (AB Science) -- provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
XBRANE.SS (Xbrane Biopharma) -- enters conditional financing solution with Fenja Capital II A/S; provides loan of SEK 60M to be triggered in event of a delay in anticipated US FDA approval of Lucamzi (proposed biosimilar to Lucentis)
3692.HK (Hansoh Pharmaceutical Group) -- enters into license agreement with Roche for HS-20110
Other
ASML.NA (ASML Holding) -- Street Takeaways - ASML Holding Q3 Results
ML.FP (Cie Generale des Etablissements Michelin SA) -- Michelin publishes global tire market data for Sep
ASC.LN (Asos) -- German tax authorities pursuing Asos over tens of millions of euros of unpaid customs duties - FT
US set to ease tariffs on US auto industry - Bloomberg
Key rating changes
Upgrades
ENTRA.NO (Entra ASA) -- to buy from hold at Pareto
HMSO.LN (Hammerson) -- Hammerson transferred overweight at Barclays; prior rating was underweight
SANOMA.FU (Sanoma) -- upgraded to buy from hold at Nordea
CON.GR (Continental) -- upgraded to buy from hold at Deutsche Bank
DYVOX.SS (Dynavox Group) -- upgraded to buy from hold at ABG Sundal Collier
Other Actions
BPE.IM (BPER Banca) -- reinstated overweight at Barclays
Data
Nikkei (1.35%) to 47627.05
Hang Seng (1.83%) to 25415.70
Shanghai Composite (1.24%) to 3867.53
S&P futures (41.0) vs prior close of 6668.8
€-$ +0.0031 or +0.26% to 1.1719
$-¥ (0.59) or (0.39%) to 149.85
€-¥ (0.21) or (0.12%) to 175.60
This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".
DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE